The effect of genetic background and immunophenotype on microglial response to AD pathology

A major hurdle in developing effective treatments for Alzheimer’s Disease (AD) is the fact that pathological hallmarks, such as amyloid beta (Aβ) plaques, develop decades before the first clinical symptoms emerge. Moreover, the risk of developing AD is strongly influenced by genetic background. In addition, the role of microglia in the disease pathway is undeniable, albeit dual and complex. We therefore aim to determine the influence of patient genetic background and immunophenotype on the microglial response to AD pathology.